
Moxetumomab pasudotox is a CD22-targeted immunotoxin.
Moxetumomab pasudotox is a CD22-targeted immunotoxin.
Racial disparities in cancer outcomes remain a challenge.
The draft guidance is open for public consultation until January 11, 2021
Approved for use in adults with and without a 17p deletion or TP53 mutation
A multistakeholder perspective on shared decision-making.
It is indicated for a rare and aggressive form of AML.
Results are from The Beat AML Trial.
Final draft guidance recommends first-line venetoclax plus obinutuzumab for untreated chronic lymphocytic leukaemia
Findings from the Italian GIMEMA LAL2116 D-ALBA trial.
Guidance on diagnosis, treatment, and follow-up are provided
Treatment should align with the patient's goals.
Findings from a network meta-analysis.
ALL should be considered as a differential diagnosis in children with severe osteoporosis and vertebral fractures.
The approval is based on the phase 3 QUAZAR AML-001 trial.